Recombinant Human IL-33 Protein(TRX Tag)

Catalog Number: PDEH100480



Note: Centrifuge before opening to ensure complete recovery of vial contents.

			•
 O C	OWI		ınn
		UU	ion

Species Human

Source E.coli-derived Human IL-33 protein His 109-Thr 270, with an N-terminal Trx

 Mol_Mass
 37.7 kDa

 Accession
 O95760

Bio-activity Not validated for activity

Properties

Purity > 95% as determined by reducing SDS-PAGE.

Endotoxin < 10 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.


ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol

Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution of

0.5 mg/mL. Concentration is measured by UV-Vis

Data



SDS-PAGE analysis of Human IL-33 proteins, 2µg/lane of Recombinant Human IL-33 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 35 KD

Background

Interleukin-33 (IL-33) was initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules. It is a 30-32 kD pro-inflammatory protein with intracellular and extracellular activities and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is highly and selectively expressed by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T(H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. Human IL-33 is 270 amino acids in length.

For Research Use Only